Inflammatory Biomarker Score Identifies Patients with Six-Fold Increased Risk of One-Year Mortality after Pancreatic Cancer

SIMPLE SUMMARY: For 20 years, the CA 19-9 blood test has been the only broadly used biomarker of pancreatic ductal adenocarcinoma (PDAC). We lack easily available biomarkers to help differentiate patients between good, intermediate and poor survivors at the time of PDAC diagnosis. Using one of the l...

Descripción completa

Detalles Bibliográficos
Autores principales: Kjaergaard, Alisa D., Chen, Inna M., Johansen, Astrid Z., Nordestgaard, Børge G., Bojesen, Stig E., Johansen, Julia S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8466571/
https://www.ncbi.nlm.nih.gov/pubmed/34572824
http://dx.doi.org/10.3390/cancers13184599

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8466571/
https://www.ncbi.nlm.nih.gov/pubmed/34572824
http://dx.doi.org/10.3390/cancers13184599

Ejemplares similares